Christoph is co-founder of T-CURX and member of T-CURX’ Scientific Advisory Board. He is an internationally renowned expert in the development of antibody-based cancer therapies and Professor at the University of Florida, following their acquisition of the Jupiter, FL, USA campus of The Scripps Research Institute (TSRI).

At TSRI, Christoph was also Associate Dean of the Skaggs Graduate School of Chemical and Biological Studies, a top ten PhD program in chemistry, biochemistry, and biology in the USA. Before his appointment at TSRI, Christoph was Group Leader at the National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda, MD, USA, from 2003 until 2012. He started his independent research career as Assistant Professor on the La Jolla, CA, USA campus of TSRI in 1999 where he also performed his postdoctoral training.

Christoph studied Biochemistry at the University of Bayreuth, Germany, and at the University of Zurich, Switzerland, where he received his PhD in 1995. A particular focus of Christoph’s research at the interface of biology and chemistry has been antibody drug and target discovery for cancer therapy, including the generation of molecularly defined antibody-drug conjugates (ADCs) and antibody-siRNA conjugates (ARCs) as well as chemically programmed T-cell engaging bispecific antibodies (T-biAbs) and chimeric antigen receptor T cells (CAR-Ts).

Christoph has published >150 journal articles and book chapters, and he has (co-)invented 21 issued and numerous pending USA patents. In addition to his academic responsibilities, he has consulted many pharma and biotech companies including NBE-Therapeutics (Basel, Switzerland; 2013-2021) and Pyxis Oncology (Cambridge, MA, USA; since 2021) as Scientific Advisory Board member.